Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

12 Week Evaluation of the Safety and Efficacy of 3 Doses of CP-526,555 and Placebo for Smoking Cessation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00139750
Recruitment Status : Completed
First Posted : August 31, 2005
Last Update Posted : June 4, 2007
Information provided by:

Brief Summary:
The purpose of the study is to examine the safety and efficacy and dose-response relationship of three doses of CP-526,555 for 12 weeks compared with placebo for smoking cessation; including post-treatment follow-up of smoking status to one year from randomization. A small satellite protocol (A3051048) investigated safety of a second course of therapy in subjects who did not quit.

Condition or disease Intervention/treatment Phase
Smoking Cessation Drug: CP-526,555 (varenicline) Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 600 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating The Efficacy And Safety Of CP-526,555 In Smokers Motivated To Stop Smoking
Study Start Date : December 2004
Actual Study Completion Date : February 2006

Resource links provided by the National Library of Medicine

Drug Information available for: Varenicline

Primary Outcome Measures :
  1. 4-week continuous quit rate (CQR) for Weeks 9-12

Secondary Outcome Measures :
  1. Continuous abstinence for Weeks 9-52 and Weeks 9-24
  2. Long-term quit rate at Week 52
  3. 4-week CQR for Weeks 4-7
  4. 7-day point prevalence of asbtinence Weeks 12, Week 24, and Week 52
  5. Continuous abstinence from TQD (Week 1) through Week 12
  6. Weekly average number of cigarettes smoked per day for Weeks 1-12
  7. Evaluation of withdrawal symptoms by the Minnesota Nicotine Withdrawal Scale
  8. Evaluation of smoking satisfaction by the Smoking Effects Inventory
  9. Evaluation of urge to smoke by the Brief Questionnaire of Smoking Urges

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Cigarette smokers who are motivated to stop smoking and have smoked an average of at least 10 cigarettes per day

Exclusion Criteria:

  • Subjects who have used a nicotine replacement product within 30 days of the study screening visit or intend to use it during the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00139750

Layout table for location information
Pfizer Investigational Site
Noda, Chiba, Japan
Pfizer Investigational Site
Sapporo, Hokkaido, Japan
Pfizer Investigational Site
Yokohama, Kanagawa, Japan
Pfizer Investigational Site
Beppu-shi, Oita-ken, Japan
Pfizer Investigational Site
Toyonaka, Osaka, Japan
Pfizer Investigational Site
Tosu, Saga, Japan
Pfizer Investigational Site
Hamamatsu, Shizuoka, Japan
Pfizer Investigational Site
Edogawa-ku, Tokyo, Japan
Pfizer Investigational Site
Minato-ku, Tokyo, Japan
Pfizer Investigational Site
Musashino, Tokyo, Japan
Pfizer Investigational Site
Setagaya-ku, Tokyo, Japan
Pfizer Investigational Site
Shinagawa-ku, Tokyo, Japan
Pfizer Investigational Site
Toshima-ku, Tokyo, Japan
Pfizer Investigational Site
Fukuoka, Japan
Pfizer Investigational Site
Ohita, Japan
Sponsors and Collaborators
Layout table for investigator information
Study Director: Pfizer Call Center Pfizer
Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information Identifier: NCT00139750    
Other Study ID Numbers: A3051046
First Posted: August 31, 2005    Key Record Dates
Last Update Posted: June 4, 2007
Last Verified: June 2007
Additional relevant MeSH terms:
Layout table for MeSH terms
Nicotinic Agonists
Cholinergic Agonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs